Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
European Regulator Recommend Additional Booster Doses of mRNA COVID-19 Vaccines
The European Centre for Disease Prevention & Control and the European Medicines Agency have recommended second booster doses of mRNA COVID-19 vaccines for people between 60 and 79.
In April 2022, the agencies recommended that people over 80 be considered for a second booster.
The move comes after a new wave is underway in Europe, with increasing hospital and intensive care unit rates.
Perrigo Files US Application For First OTC Birth Control Pill
Perrigo Company plc's (NYSE: PRGO ) HRA Pharma has submitted its application to the FDA for the first-ever over-the-counter (OTC) birth control pill.
The company has applied for an Rx-to-OTC switch for Opill, a progestin-only daily birth control pill (also referred to as a mini pill or non-estrogen pill).
Shares are up 2.31% at $42.05 during the premarket session.
Ionis Partner Licenses Rare Kidney Disease Treatment
Ionis Pharmaceuticals Inc (NASDAQ: IONS ) said that its long-standing partner, Roche Holdings AG (OTC: RHHBY ), will license and advance IONIS-FB-LRx, an investigational antisense medicine, into a Phase 3 study immunoglobulin A nephropathy.
Roche's decision to advance the program comes after positive data from a Phase 2 ...
Full story available on Benzinga.com